Drugs / recombinant vaccinia-CEA(6D)-TRICOM vaccine
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00052351 | Sep 2002 → Oct 2007 | female breast carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT00091039 | Aug 2004 → Feb 2006 | lung cancer | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 1 | NCT00217373 Background | Jun 2005 → Jan 2013 | neoplasm | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT00088933 Background | Jun 2004 → Nov 2007 | non-small cell lung carcinoma, rectal carcinoma, small cell lung carcinoma | National Cancer Institute (NCI) | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | recombinant vaccinia-CEA(6D)-TRICOM vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00052351 ↗ |
| Known as | vaccinia-CEA-TRICOM vaccine | “Patients receive vaccinia-CEA-TRICOM vaccine subcutaneously (SC) on day 0 and fowlpox-CEA-TRICOM (rF-CEA-TRICOM) vaccine SC on days 14, 29, 43, 57, 70, 91, and 112.” NCT00091039 ↗ |
| Action | Deplete | “Vaccines may make the body build an immune response to kill tumor cells.” NCT00088933 ↗ |
| Modality | Vaccine | “Vaccines made from a gene-modified virus may make the body build an immune response to kill tumor cells.” NCT00052351 ↗ |
| Route | Subcutaneous | “all patients receive vaccinia-CEA-TRICOM vaccine subcutaneously (SC) on day 1” NCT00052351 ↗ |